Resveratrol inhibits firefly luciferase.
The potential therapeutic value of resveratrol in age-related disease settings including cancer, diabetes, and Alzheimer's has emerged from a rapidly growing body of experimental evidence. Protection from oxidative stress appears to be a common feature of resveratrol that may be mediated through SirT1, though more specific molecular mechanisms by which resveratrol mediates its effects remain unclear. This has prompted an upsurge in cell-based mechanistic studies, often incorporating reporter assays for pathway elucidation in response to resveratrol treatment. Here, we report that resveratrol potently inhibits firefly luciferase with a K(i) value of 2microM, and caution that this confounding element may lead to compromised data interpretation.
Bakhtiarova
Adel
A
Diabetes and Metabolism Disease Area, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139, USA.
Taslimi
Paul
P
Elliman
Stephen J
SJ
Kosinski
Penelope A
PA
Hubbard
Brian
B
Kavana
Michael
M
Kemp
Daniel M
DM
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D002460:Cell Line; D017930:Genes, Reporter; D049409:Luciferases, Firefly / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D051379:Mice; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*
D000975:Antioxidants; D013267:Stilbenes; D049409:Luciferases, Firefly; D000077185:Resveratrol